Targeting BCMA in multiple myeloma: designs, challenges, and future directions

• Published in: Cancer Immunology, Immunotherapy : CII Vol. 74; no. 3; pp. 77 - 16
• Main Authors: Hu, Yi, Xie, Yuetao, Wang, Xiaodong, Yang, Lufeng, Geng, He, Yi, Zugang, Zhang, Yao, Ma, Lin, Chen, Fang
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2025; Springer Nature B.V; Springer
• Subjects: Animals; Antigens; B cell maturation antigen; B-Cell Maturation Antigen - antagonists & inhibitors; B-Cell Maturation Antigen - immunology; Blood cancer; Cancer Research; Cell therapy; Chimeric antigen receptor; Chimeric antigen receptors; Design; Drug development; Humans; Immunology; Immunotherapy; Immunotherapy, Adoptive - methods; Lymphocytes; Lymphocytes T; Malignancy; Medicine; Medicine & Public Health; Multiple myeloma; Multiple Myeloma - immunology; Multiple Myeloma - therapy; Oncology; Receptors, Chimeric Antigen - immunology; Review; T cells; Toxicity; Chimeric antigen receptor; T cells; B cell maturation antigen; Immunotherapy; Multiple myeloma

Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the developmen...